BOOSTER (Pfizer and Moderna) & PAEDIATRIC Pfizer (5-11 years) Available at Milsons Point Medical Centre
BOOSTER (Pfizer and Moderna)
If you are 16 and over you can book for a BOOSTER Dose (Pfizer or Moderna) with us easily ONLINE through our website or via HotDoc app. Please book a COVID vaccine (Pfizer or Moderna) dose THREE type appointment.
Booster shots are now available to all fully vaccinated people aged 16 years and older, three months or more from their second COVID-19 dose.
Pfizer and Moderna
Pfizer and Moderna are the preferred Booster vaccine
For 16-18 years Pfizer is the only approved Booster Vaccine
For 18+ Pfizer or Moderna can be used as a booster
AstraZeneca is no longer recommended as a booster – even if you have previously had AstraZeneca.
The only reason for the use of AstraZeneca as a Booster is if you have has a medical contraindication to the mRNA vaccine.
- If we did not provide you with your first or second dose, please bring with your proof of your previous vaccines.
Further information is also available on the ATAGI statement.
Winter Dose ( Second Booster)
The ATAGI has recommended that an additional booster is given to the following people:
- Adults aged 65 years and older
- Residents of aged care or disability care facilities
- People aged 16 years and older with severe immunocompromise
- Aboriginal and Torres Strait Islander people aged 50 years and older
The additional booster is recommended from 4 months or longer from your previous Covid-19 vaccination, or four months after a confirmed SARS-CoV-2 infection, if the infection occurred since the persons first COVID-19 Booster dose .
The Influezna vaccine can be administered at the same time
Appointments for this booking type will be made available from the 4th of April 2022
Further information is also available on the ATAGI Statement
Paediatric Pfizer (5-11 Years)
We will be receiving the paediatric formulation of the Pfizer vaccine from 10 January 2022. You can now book for FIRST and SECOND doses (8 weeks apart) Paediatric Pfizer (5-11 yrs) with us easily ONLINE through our website or via HotDoc app. Please make sure that you book for BOTH FIRST and SECOND doses.
Only Pfizer is approved for use in children and is the only vaccine that have a paediatric formulation available. Your child will require 2 doses, 8 weeks apart (but this can be brought forward to 3 weeks in specific circumstances). More detailed information about the vaccine can be found in the ATAGI recommendation.
If your child is aged 11 years and has the paediatric formulation for their first dose, and then turns 12 years of age before their second dose, they should have the adult Pfizer formulation as their second dose.
The Pfizer paediatric vaccine can be co-administered with other vaccines.
Please note that this is specifically for patients who have conditions which could have impaired their response to the first and second dose of the COVID Vaccine. BOOSTER DOSE (as explained above) is different to what is referred to as DOSE 3.
The Commonwealth Government has advised that people with impaired immune function or who are taking medications that impair immunity should have a THIRD dose of the COVID-19 vaccine to complete their primary course.
An mRNA vaccine (Pfizer) is preferred to Vaxzevria (AstraZeneca) for this 3rd dose. AstraZeneca can be used for the 3rd dose for individuals who have received AstraZeneca for their first 2 doses if there are no contraindications or precautions for use, or if a significant adverse reaction has occurred after a previous mRNA vaccine dose which contraindicates further doses of mRNA vaccine (e.g., anaphylaxis, myocarditis).
The recommended interval for the 3rd dose is 2 to 6 months after the 2nd dose of vaccine (vs BOOSTER dose which is to be received 6 months or more after the 2nd dose). A minimum interval of 4 weeks may be considered in exceptional circumstances (e.g., anticipated intensification of immunosuppression; outbreaks).
Immunocompromising conditions and therapies for which a 3rd primary dose is recommended:
- Active haematological malignancy
- Non-haematological malignancy with current active treatment including chemotherapy, radiotherapy, and/or hormonal therapy, but excluding immunotherapy with immune checkpoint inhibitors
- Solid organ transplant with immunosuppressive therapy
- Haematopoietic stem cell transplant (HSCT) recipients or chimeric antigen receptor T-cell (CAR-T) therapy within 2 years of transplantation.
- These patients require revaccination with 3 additional doses of COVID-19 vaccine, irrespective of doses given prior to transplantation, commencing generally ≥3-6 months after their transplant after discussion with their treating specialist.
- Those beyond 2 years from transplant should discuss with their treating specialist about the need for a 3rd dose.
- Immunosuppressive therapies including:
- High dose corticosteroid treatment equivalent to >20mg/day of prednisone for ≥14 days in a month, or pulse corticosteroid therapy.
- Multiple immunosuppressants where the cumulative effect is considered to be severely immunosuppressive.
- Selected conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDS):
- including mycophenolate, methotrexate (>0.4 mg/kg/week), leflunomide, azathioprine (>3mg/kg/day), 6-mercaptopurine (>1.5 mg/kg/day), alkylating agents (e.g. cyclophosphamide, chlorambucil), and systemic calcineurin inhibitors (e.g. cyclosporin, tacrolimus)
- excluding hydroxychloroquine or sulfasalazine when used as monotherapy
- Biologic and targeted therapies anticipated to reduce the immune response to COVID-19 vaccine:
- including B cell depleting agents (e.g. anti-CD20 monoclonal antibodies, BTK inhibitors, fingolimod), anti-CD52 monoclonal antibodies (alemtuzumab), anti-complement antibodies (e.g. eculizumab), anti-thymocyte globulin (ATG) and abatacept
- excluding agents with likely minimal effect on vaccine response such as immune checkpoint inhibitors, anti-integrins, anti-TNF-α, anti-IL1, anti-IL6, anti-IL17, anti-IL4 and anti-IL23 antibodies.
- Primary immunodeficiency including combined immunodeficiency and syndromes, major antibody deficiency (e.g., common variable immune deficiency (CVID) or agammaglobulinemia), defects of innate immunity (including phagocytic cells), defects of immune regulation, complement deficiencies and phenocopies of primary immunodeficiencies.
- Advanced or untreated HIV with CD4 counts <250/μL or those with a higher CD4 count unable to be established on effective antiretroviral therapy
- a 3rd primary dose is not required for people living with HIV, receiving ART with CD4 counts ≥250/μL
- Long term haemodialysis or peritoneal dialysis
In August Alone, We Administered More Than 2500 doses of COVID vaccine…
Please Read The Following Before Booking Your Appointments For the First and Second Doses of Pfizer Vaccine
- You can easily book your appointments ONLINE through our website or via HotDoc app for your FIRST and SECOND doses (3 to 6 weeks after the FIRST dose) of Pfizer vaccine. Please make sure that you book for BOTH FIRST and SECOND doses.
- All People aged 12 years and above are now eligible to receive Pfizer vaccine